The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure
Abstract
Hepatorenal syndrome (HRS) carries a high short‐term mortality in patients with cirrhosis and acute on chronic liver failure (ACLF). Terlipressin and noradrenaline are routinely used in cirrhosis with HRS and have been found to be equally effective. There are no data comparing the efficacy of terlipressin with noradrenaline in ACLF patients with HRS. In an open‐label, randomized controlled trial (RCT), consecutive patients with ACLF diagnosed with HRS acute kidney injury (AKI) were randomized to albumin with infusion of terlipressin (2‐12 mg/day; n = 60) or noradrenaline (0.5‐3.0 mg/h; n = 60). Response to treatment, course of AKI, and outcome were studied. Baseline characteristics, including AKI stage and sepsis‐related HRS‐AKI, were comparable between groups. Compared to noradrenaline, terlipressin achieved greater day 4 (26.1% vs. 11.7%; P = 0.03) and day 7 (41.7% vs. 20%; P = 0.01) response. Reversal of HRS was also better with terlipressin (40% vs. 16.7%; P = 0.004), with a significant reduction in the requirement of renal replacement therapy (RRT; 56.6% vs. 80%; P = 0.006) and improved 28‐day survival (48.3% vs. 20%; P = 0.001). Adverse events limiting use of drugs were higher with terlipressin than noradrenaline (23.3% vs. 8.3%; P = 0.02), but were reversible. On multivariate analysis, high Model for End‐Stage Liver Disease (MELD; odds ratio [OR], 1.10; confidence interval [CI] = 1.009‐1.20; P = 0.03) and noradrenaline compared to terlipressin (OR, 3.05; CI = 1.27‐7.33; P = 0.01) predicted nonresponse to therapy. Use of noradrenaline compared to terlipressin was also predictive of higher mortality (hazard ratio [HR], 2.08; CI = 1.32‐3.30; P = 0.002). Conclusion: AKI in ACLF carries a high mortality. Infusion of terlipressin gives earlier and higher response than noradrenaline, with improved survival in ACLF patients with HRS‐AKI.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
Self-citation
Cited by
APASL ACLF Research Consortium (AARC) for APASL ACLF working Party., Sarin, S. K., Choudhury, A., Sharma, M. K., Maiwall, R., Al Mahtab, M., Rahman, S., Saigal, S., Saraf, N., Soin, A. S., et al. (2019) · Hepatology International · doi:10.1007/s12072-019-09946-3 · Cited by 884
Self-citationAngeli, P., Garcia-Tsao, G., Nadim, M. K., & Parikh, C. R. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.07.002 · Cited by 432
Acute-on-chronic liver failure: Objective admission and support criteria in the intensive care unit
Dong, V., & Karvellas, C. J. (2019) · JHEP Reports · doi:10.1016/j.jhepr.2019.02.005 · Cited by 38
Metadata
- Authors
- Arora, V., Maiwall, R., Rajan, V., Jindal, A., Muralikrishna Shasthry, S., Kumar, G., Jain, P., & Sarin, S. K.
- Venue
- Hepatology
- Published
- 2019-02-20
- Volume
- 71
- Issue
- 2
- Pages
- 600-610
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2895004242
- Cited by
- 205
- References
- 1
- FWCI
- 10.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure. https://app.cochat.ai/papers/10.1002/hep.30208
- The paper
- Arora, V., Maiwall, R., Rajan, V., Jindal, A., Muralikrishna Shasthry, S., Kumar, G., Jain, P., & Sarin, S. K. (2020). Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure. Hepatology. https://doi.org/10.1002/hep.30208
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.